Abbott Laboratories vs. SELLAS Life Sciences Group, Inc. Common Stock
ABT
Abbott Laboratories
$116.64 +2.19%
VS SLSSELLAS Life Sciences Group, Inc. Common Stock
$15.46 +15.37%
SELLAS Life Sciences Group, Inc. Common Stock (SLS) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| ABT | SLS | |
|---|---|---|
| Market Cap | $201.83 billion | $3.12 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | SLS | |
|---|---|---|
| P/E Ratio | 37.75 | — |
| Price / Book | 3.90 | — |
| Price / Sales | 4.33 | — |
ABT and SLS split the valuation factors evenly.
Profitability
| ABT | SLS | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and SLS split the profitability factors evenly.
Dividend
| ABT | SLS | |
|---|---|---|
| Dividend Yield | 2.16% | 6.22% |
| Payout Ratio | 81.55 | — |
SLS leads on 1 of 1 dividend factors.
Risk & Sentiment
| ABT | SLS | |
|---|---|---|
| Short Interest | 0.57% | 0.06% |
SLS leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, SLS overview, SLS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.